[
 {
  "nct": "NCT00090220",
  "coder_1": "equal",
  "coder_1_reason": "Both Base Study groups were 'followed up to approximately Month 48'; open-label qHPV for placebo recipients in EXT1 is reported in its own group (EG002).",
  "coder_2": "equal",
  "coder_2_reason": "Base-study vaccine and placebo groups are both followed to approx. Month 48; EXT1 and LTFU are separate groups."
 },
 {
  "nct": "NCT00092521",
  "coder_1": "equal",
  "coder_1_reason": "Groups 1, 2 and 3 (placebo) are each described as followed 'from completion of the Vaccination Period at Month 7 through Month 48'; the extension is reported separately as Group 4.",
  "coder_2": "equal",
  "coder_2_reason": "Base-study groups for vaccine and placebo both run through Month 48; the extension is its own Group 4."
 },
 {
  "nct": "NCT00092534",
  "coder_1": "equal",
  "coder_1_reason": "Both compared groups are Base Study groups; placebo recipients' qHPV vaccination is reported in the separate 'Base Study EXT' group (EG002) and later follow-up in the LTFU cohorts, so each side covers the base study.",
  "coder_2": "unclear",
  "coder_2_reason": "Placebo group EG001 is described as getting qHPV 'during the 4-year Base Study EXT' while the vaccine group is followed 'up to 4 years', yet EXT is also its own group (EG002); the record conflicts."
 },
 {
  "nct": "NCT00092547",
  "coder_1": "equal",
  "coder_1_reason": "For both base groups 'Adverse events are reported for this group from Day 1 to Month 30'; Month 30 to 126 is reported in separate extension groups.",
  "coder_2": "equal",
  "coder_2_reason": "Both base groups are reported Day 1 to Month 30; extension follow-up is in separate groups."
 },
 {
  "nct": "NCT00119067",
  "coder_1": "equal",
  "coder_1_reason": "All groups, placebo included, have the same per-injection windows ('14 days post-injection for the first two injections, and 28 days for all subsequent'), with no crossover in the compared groups.",
  "coder_2": "equal",
  "coder_2_reason": "Fixed post-injection AE windows (14/28 days) after the same dosing schedule for vaccine and placebo."
 },
 {
  "nct": "NCT00239577",
  "coder_1": "unclear",
  "coder_1_reason": "SAEs run 'from Day 0 up to Month 6 post-booster vaccination', but only the 17b and 19 vaccine groups had a booster, and the record doesn't say how long the placebo and 17a groups were followed for SAEs.",
  "coder_2": "equal",
  "coder_2_reason": "Safety is throughout one study period (SAEs to Month 6 post-booster) and fixed post-dose windows for all groups; no unblinding or crossover mentioned."
 },
 {
  "nct": "NCT00350337",
  "coder_1": "equal",
  "coder_1_reason": "Solicited and unsolicited AEs are counted for the same fixed windows after each vaccination (21 and 31 days) for every group, placebo included.",
  "coder_2": "equal",
  "coder_2_reason": "Same fixed windows (21 days solicited, 31 days unsolicited) after vaccination for all groups."
 },
 {
  "nct": "NCT00365378",
  "coder_1": "equal",
  "coder_1_reason": "AEs 'were collected from Day 1 until Month 7' for both base groups, and the extension is reported as a separate group (EG002).",
  "coder_2": "equal",
  "coder_2_reason": "Base groups AEs Day 1 to Month 7; the extension is a separate group."
 },
 {
  "nct": "NCT00857311",
  "coder_1": "equal",
  "coder_1_reason": "Same windows for both groups: injection-site AEs to 5 days, systemic AEs to 29 days after each vaccination, SAEs 'for the entire study period (Week 260)'.",
  "coder_2": "equal",
  "coder_2_reason": "Identical schedule and the same AE windows (5/29 days, SAEs whole study) for both groups."
 },
 {
  "nct": "NCT01047345",
  "coder_1": "equal",
  "coder_1_reason": "Both compared groups are 'Base Study' groups; placebo recipients' open-label 9vHPV is reported in the separate 'Extension Study' group (EG002).",
  "coder_2": "equal",
  "coder_2_reason": "Base-study groups are reported separately from the open-label Extension group."
 },
 {
  "nct": "NCT01245764",
  "coder_1": "unclear",
  "coder_1_reason": "SAEs were 'assessed up to 19 months from study start' with no Phase B group, while vaccine recipients 'did not continue to study Phase B' and placebo recipients could get GARDASIL in Phase B, so it can't be told whether the placebo group's SAEs run through Phase B.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT01310413",
  "coder_1": "equal",
  "coder_1_reason": "Blinded-phase groups both report SAEs Day 0 to Day 385; the unblinded phase (Day U0 to U385) is reported in the separate Placebo/H5N1 group (EG002).",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT01545375",
  "coder_1": "equal",
  "coder_1_reason": "Both groups got the same primary and booster schedule, with SAEs 'during the whole study period (from Day 0 to Month 22)' and the same post-vaccination windows.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT01992536",
  "coder_1": "equal",
  "coder_1_reason": "Every group, booster or saline, has the same windows: solicited AEs Day 1 to 7, unsolicited to Day 30, SAEs and others Day 1 to Day 365.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT02075203",
  "coder_1": "vaccine_longer",
  "coder_1_reason": "The BCG group, a vaccine group in the comparison, has injection-site AEs counted for '84 days post vaccination' against '28 days' for the placebo group.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups.",
  "note": "A reviewer of the study's first version pointed out that coder 1's reason concerns injection-site reactions (84 against 28 days); the record's time frame gives serious adverse events the same window, the entire study period, in every group."
 },
 {
  "nct": "NCT02302066",
  "coder_1": "equal",
  "coder_1_reason": "All groups get three injections (vaccine or placebo-matching) on Days 1, 91 and 365, with SAEs 'through end of study (Day 540)' and other AEs 28 days after each.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT02315703",
  "coder_1": "vaccine_longer",
  "coder_1_reason": "'SAEs were reported up to Week 336 for Group 1 and 2 and up to Week 96 for the other groups', including placebo Group 8, since only Groups 1 and 2 entered the long-term extension.",
  "coder_2": "vaccine_longer",
  "coder_2_reason": "SAEs were reported 'up to Week 336 for Group 1 and 2 and up to Week 96 for the other groups' including placebo Group 8."
 },
 {
  "nct": "NCT02561195",
  "coder_1": "equal",
  "coder_1_reason": "The compared vaccine and placebo groups are each 'followed up to 12 months after the last vaccination'; the fourth-dose extension is reported in separate groups (EG006 to EG013).",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT02564523",
  "coder_1": "equal",
  "coder_1_reason": "Placebo groups mirror the vaccine groups, placebo subsets getting a placebo booster at Day 365, and the time frame is 'Up to 3 years and 3 months' for all.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT02623725",
  "coder_1": "equal",
  "coder_1_reason": "Booster and placebo groups share the windows: AEs to 28 days post-injection, SAEs 'up to 24 months after last vaccination'.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT02747927",
  "coder_1": "equal",
  "coder_1_reason": "'AEs are reported separately for Placebo and TDV arms of each Part', and Parts 2 to 5 have their own groups, so the compared groups both cover Part 1.",
  "coder_2": "equal",
  "coder_2_reason": "AEs are 'reported separately for Placebo and TDV arms of each Part'; the compared groups are both Part 1 with other AEs only up to 28 days post vaccination."
 },
 {
  "nct": "NCT02788045",
  "coder_1": "vaccine_longer",
  "coder_1_reason": "The Ad26.Mos4.HIV group goes on into the long-term extension (time frame 'Up to Week 264', SAEs from the extension counted), while placebo participants 'were followed up till Week 72'.",
  "coder_2": "vaccine_longer",
  "coder_2_reason": "Vaccine group EG000 includes the optional long-term extension (TF up to Week 264), while the placebo group was 'followed up till Week 72'."
 },
 {
  "nct": "NCT02824198",
  "coder_1": "equal",
  "coder_1_reason": "Booster and placebo groups share the windows: AEs to 28 days post-booster, SAEs 'up to 24 months after booster injection'.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT02873286",
  "coder_1": "equal",
  "coder_1_reason": "The compared groups are the two-dose arms and placebo, none boosted, with non-serious AEs 'within 4 weeks after each vaccination'; the 108-week booster follow-up belongs to the booster groups, which are not compared.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT02935686",
  "coder_1": "vaccine_longer",
  "coder_1_reason": "Groups 1 and 2 report AEs 'up Week 216 for participants entering the LTE', while placebo 'Group 3: Baseline up to Week 72'.",
  "coder_2": "vaccine_longer",
  "coder_2_reason": "Vaccine Groups 1 and 2 are reported through the LTE to Week 216, whereas placebo Group 3 is 'Baseline up to Week 72'."
 },
 {
  "nct": "NCT03682107",
  "coder_1": "equal",
  "coder_1_reason": "Same windows for all groups: non-serious AEs 'through 28 days following the final vaccination, up to Day 197', SAEs through Day 337.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT03765073",
  "coder_1": "equal",
  "coder_1_reason": "Primary-dose groups share each stage's time frame, and Stage 1 boosters, given to former vaccine and placebo recipients alike, are reported in separate booster groups.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT03952650",
  "coder_1": "unclear",
  "coder_1_reason": "The time frame lists 'seven months for booster phase', but no group reports a booster phase and the record doesn't say who was boosted, so it can't be told whether the compared groups' tables include it.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT03970733",
  "coder_1": "equal",
  "coder_1_reason": "All main-phase groups report unsolicited AEs and SAEs 'up to Day 545'; the booster phase is reported in separate groups (EG003, EG004).",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT03999996",
  "coder_1": "equal",
  "coder_1_reason": "Booster TDV and booster placebo groups share the same SAE and non-serious windows after the Month 15 or Month 42 dose.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT04228783",
  "coder_1": "equal",
  "coder_1_reason": "Each placebo group is matched with its vaccine cohort: Day 237 for Groups 1 to 4 and Day 537 for booster-cohort Groups 5 and 6, both sides including both cohorts.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT04368728",
  "coder_1": "vaccine_longer",
  "coder_1_reason": "'The PC Fup Period was approx. 18 months for BNT162b2 group (approx. 6 months of blinded Fup period + approx. 12 months OL follow up period ...), approx. 6 months for Placebo group (before cross-over)'.",
  "coder_2": "vaccine_longer",
  "coder_2_reason": "Description says the PC follow-up was approx. 18 months for BNT162b2 (6 blinded + 12 open-label) but approx. 6 months for placebo before cross-over."
 },
 {
  "nct": "NCT04405076",
  "coder_1": "equal",
  "coder_1_reason": "Part A groups for vaccine and placebo cover Part A; Part B, entered by participants on either side who chose unblinding, is reported in separate Part B groups.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT04470427",
  "coder_1": "equal",
  "coder_1_reason": "Part A collection runs '1st dose to PDV/unblinding/BD/last date observed, whichever was earliest' for both arms, with Part B and Part C in separate groups.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT04505722",
  "coder_1": "equal",
  "coder_1_reason": "Both double-blind groups report SAEs 'Baseline (Day 1) up to 35 weeks' and other AEs to 28 days after vaccination; open-label data go to the 'All participants' and booster groups.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT04516746",
  "coder_1": "equal",
  "coder_1_reason": "'Adverse events data reported for double-blind period only' for both arms.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT04535453",
  "coder_1": "unclear",
  "coder_1_reason": "The placebo groups' descriptions include the crossover to active Ad26.COV2.S (Amendment 5, or about 6 months for Group C) and no separate crossover group exists, with the time frame 'Up to 1.5 years', so it can't be told whether placebo reporting stops at crossover or includes post-crossover vaccination.",
  "coder_2": "unclear",
  "coder_2_reason": "Placebo group descriptions mention Amendment 5 crossover to active vaccine but do not say whether placebo reporting stops at unblinding; TF is 'Up to 1.5 years' for all."
 },
 {
  "nct": "NCT04588480",
  "coder_1": "equal",
  "coder_1_reason": "BNT162b2 and placebo groups were both 'followed up to 12 months after last dose', and placebo recipients' later BNT162b2 is reported in the separate 'Placebo Then BNT162b2' group.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT04614948",
  "coder_1": "equal",
  "coder_1_reason": "Both double-blind groups report SAEs 'From Day 1 till end of DB phase (up to 7.2 months)', and open-label data go to the 'All Participants' group.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT04635423",
  "coder_1": "equal",
  "coder_1_reason": "Both compared groups are 'Base Study' groups; the open-label extension is reported in separate groups for former vaccine and placebo recipients.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT04649151",
  "coder_1": "equal",
  "coder_1_reason": "Both compared groups are Part 1A, defined in the arms as the 'Blinded Phase'; placebo recipients' crossover is reported in the Part 1B group and boosters in Part 1C groups.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT04652102",
  "coder_1": "equal",
  "coder_1_reason": "'Participants who became unblinded and/or received a licensed/authorized vaccine were censored at the day after unblinding', applied to both arms alike.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT04668339",
  "coder_1": "equal",
  "coder_1_reason": "Primary groups A to D all report 'Vaccination 1 and 2: Day 1 up to Day 207'; the booster period is reported in separate groups E1 to H1.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT04754594",
  "coder_1": "vaccine_longer",
  "coder_1_reason": "Maternal SAEs run 'up to 6 months after delivery (approx 10 M) (BNT162b2 30 mcg) and up to 1 M after delivery (approx 5 M) (placebo)', when placebo recipients were unblinded and vaccinated.",
  "coder_2": "vaccine_longer",
  "coder_2_reason": "SAEs followed to 6 months after delivery for BNT162b2 but only 'up to 1 M after delivery (approx 5 M)' for placebo, which was unblinded at 1 month post-delivery."
 },
 {
  "nct": "NCT04796896",
  "coder_1": "unclear",
  "coder_1_reason": "Placebo groups end at crossover ('Adverse Events were collected from the first cross-over dose' in separate crossover groups), but the record doesn't say when the Part 2 mRNA-1273 groups' reporting stops within the 'Up to 2 years' time frame.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT04801420",
  "coder_1": "equal",
  "coder_1_reason": "Placebo recipients got placebo in both Part A and Part B, and all groups report SAEs up to Month 48 and other AEs 28 days after each vaccination.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT04816643",
  "coder_1": "equal",
  "coder_1_reason": "Both compared sides are 'Blinded Phase' D1-D2 groups 'in blinded placebo-controlled follow-up period'; open-label vaccination of placebo recipients is reported in separate OL groups.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT04887948",
  "coder_1": "equal",
  "coder_1_reason": "Both the coadministration group and the BNT162b2-plus-saline group 'were followed up for 6 months after vaccination'.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT04904549",
  "coder_1": "equal",
  "coder_1_reason": "Stage 1 and 2 vaccine and placebo groups all report 'up to end of follow-up, 387 days'; crossover and booster are reported in separate groups.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT04917861",
  "coder_1": "equal",
  "coder_1_reason": "All main study groups report SAEs Day 1 through Day 196; the extension to Day 700 is reported in separate groups for every arm.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT04955626",
  "coder_1": "vaccine_longer",
  "coder_1_reason": "The SSA vaccine group covers the 'Blinded and Open Label Period' while the SSA placebo group covers the 'Blinded Period' only, original placebo recipients' open-label period being a separate group.",
  "coder_2": "vaccine_longer",
  "coder_2_reason": "SSA vaccine group EG000 is 'Blinded and Open Label Period' while placebo EG001 is 'Blinded Period' only."
 },
 {
  "nct": "NCT04956575",
  "coder_1": "equal",
  "coder_1_reason": "Single injection on Day 1 for all Phase 1/2 groups, with AEs 'Up to 6 months (Day 181, end of study)'.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT05330975",
  "coder_1": "equal",
  "coder_1_reason": "Each comparison stays within one part with a shared time frame (Day 181 for Part A, Day 211 for Part B); Part C revaccination is a separate group.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT05397119",
  "coder_1": "equal",
  "coder_1_reason": "Every group, saline placebo included, got the same IM H5N1 booster and is followed 'Through the completion of the study (Day 393)'.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT05626803",
  "coder_1": "equal",
  "coder_1_reason": "Single dose for all groups, with TEAEs 'Up to Day 29' and SAEs 'Up to Day 180'; open-label sentinels are a separate group.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT05634811",
  "coder_1": "equal",
  "coder_1_reason": "Placebo recipients got a placebo injection at Month 18 as vaccine recipients got the booster, and SAEs run 'through 6 months post study Vaccination 4' for both.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT05639894",
  "coder_1": "equal",
  "coder_1_reason": "Compared groups share each stage's time frame (Day 365 for Stage 1 cohorts, Day 180 for Stage 2), with the booster cohort reported separately.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT05842967",
  "coder_1": "equal",
  "coder_1_reason": "Substudy A RSVpreF and placebo share the windows: AEs within 1 month, SAEs 'up to 6 months'.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT05903183",
  "coder_1": "equal",
  "coder_1_reason": "Both compared groups are 'Main Trial Part' groups; the observational extension is reported in separate groups for vaccine and placebo.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 },
 {
  "nct": "NCT06134804",
  "coder_1": "equal",
  "coder_1_reason": "The compared groups are both 'Post-dose 1' groups (Day 1 to Day 30); the Day 30 dose, ExPEC9V for the control arm, is reported in separate post-dose 2 groups.",
  "coder_2": "equal",
  "coder_2_reason": "Compared groups are the blinded or same-schedule groups with the same fixed AE windows or period; crossover, open-label or booster periods are reported in other groups."
 }
]